NASDAQ:ELOX
Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. The diluted share count rose 228.5%.Summary generated from Eloxx Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+228.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 6 | 0 |
| Operating income | −66 | −34 | −17 | −2 | −6 |
| Net income | −67 | −36 | −17 | −3 | −6 |
| Free cash flow | −35 | −32 | n/a | n/a | n/a |
Recent filings
- S-1Registration statement
Sep 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 4Insider transaction report
Jun 17, 2026 - 4Insider transaction report
Jun 10, 2026 - 8-KDirector or officer change
Jun 1, 2026 - S-1Registration statement
May 7, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026